Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Onglyza pancreatitis and pancreatic cancer cases. Here at Leading Justice, we can customize your firm’s Onglyza advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Onglyza advertising, plus a fee for every case we sign, and any data we generate for your firm belongs to you. In addition, we cross-qualify all of our contacts, meaning any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using state-of-the-art approaches to target contacts specifically related to Onglyza diabetes treatment and side effects like pancreatitis, heart failure and pancreatic cancer, Leading Justice will increase your firm’s Onglyza case load. If you are interested in helping victims of alleged Onglyza side effects, our extensive consumer reach and direct advertising techniques give you the competitive edge and confidence to allocate your full budget, with the knowledge that your money is being used in the best way possible.
Each and every law firm we work with at Leading Justice plays a part in determining how we classify claims as qualified or not. Our experience working with plaintiff law firms helps us recognize a great case when we see one, but we will customize our Onglyza case intake specifications to the exact criteria you are seeking. If your firm has specific Onglyza qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Onglyza data with zero chance of fraud.
Onglyza Side Effect Litigation
Incretin mimetic diabetes drugs like Onglyza (saxagliptin) are commonly used in combination with diet and exercise to help control blood glucose levels in adults with Type 2 diabetes. The prescription medications work by mimicking the functions of the natural incretin hormones in the body, thereby lowering blood sugar levels and reducing the risk of diabetes complications. However, recent research has shown that diabetes patients taking Onglyza may actually face a higher-than-expected risk of hospitalization from heart failure, pancreatitis, pancreatic cancer, cardiac arrest, thyroid cancer and other serious injuries. According to a review of clinical trial data published in the New England Journal of Medicine in April 2015, incretin mimetic diabetes drugs like Onglyza appear to increase a patient’s risk of hospitalization for heart failure by as much as 27%.
In a series of drug safety communications issued by the FDA over the past several years, the agency has warned consumers and the medical community that Onglyza and other incretin mimetic diabetes drugs may put users at risk for potentially life-threatening medical complications. In April 2015, the FDA conducted its own review of the latest incretin mimetic clinical trial data, and reported that patients who use Onglyza may be considerably more likely to develop heart failure, and may also be more likely to die. In response to these risks, future Onglyza claims are expected to be brought by patients across the country who believe they have been harmed by side effects of AstraZeneca’s blockbuster diabetes drug.
